|
ZCCHC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.96263014121223E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.25459975741649E-10 |
| Normal-vs-Stage2 |
1.30480000004596E-06 |
| Normal-vs-Stage3 |
2.28340002461636E-09 |
| Normal-vs-Stage4 |
1.55909996024661E-09 |
| Stage1-vs-Stage2 |
9.711600E-01 |
| Stage1-vs-Stage3 |
1.496230E-01 |
| Stage1-vs-Stage4 |
9.293600E-02 |
| Stage2-vs-Stage3 |
3.686400E-01 |
| Stage2-vs-Stage4 |
1.699760E-01 |
| Stage3-vs-Stage4 |
6.342000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.31306077122417E-12 |
| Normal-vs-AfricanAmerican |
3.383500E-04 |
| Normal-vs-Asian |
3.239500E-04 |
| Caucasian-vs-AfricanAmerican |
5.728600E-01 |
| Caucasian-vs-Asian |
3.306400E-02 |
| AfricanAmerican-vs-Asian |
3.745600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.35713703900365E-13 |
| Normal-vs-Female |
1.34929956097096E-10 |
| Male-vs-Female |
7.971900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.76069944682433E-10 |
| Normal-vs-Age(41-60Yrs) |
1.66850000482555E-09 |
| Normal-vs-Age(61-80Yrs) |
6.08780026389866E-10 |
| Normal-vs-Age(81-100Yrs) |
7.809400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.545000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.532200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.921000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.746200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.153600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.694600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.770200E-02 |
| Classical-VS-Follicular |
3.981000E-01 |
| Classical-VS-Other |
3.325400E-01 |
| Classical-VS-Normal |
2.69470001867944E-10 |
| Tall-VS-Follicular |
2.753800E-01 |
| Tall-VS-Other |
9.912800E-01 |
| Tall-VS-Normal |
1.84090000021619E-07 |
| Follicular-VS-Other |
5.628600E-01 |
| Follicular-VS-Normal |
1.52459999958054E-07 |
| Other-VS-Normal |
3.218700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.39489994502406E-09 |
| Normal-vs-N1 |
2.79349999798839E-08 |
| N0-vs-N1 |
3.084600E-01 |
|
|
